Novartis AG (NYSE: NVS) announced Monday that it is adding to its immunomodulatory medicine portfolio with with an acquisition. What Happened Novartis said it's acquiring IFM Tre, a subsidiary of IFM ...

Novartis is handing over $310 million up front to acquire IFM Therapeutics’ inflammation-centered subsidiary, IFM Tre. The deal includes up to $1.265 billion in milestones and gives Novartis access to ...

IFM Investors Pty is in talks to raise about 1.6 billion Swiss francs ($2 billion) in debt to back its acquisition of Swiss data center operator Green Group AG, people with knowledge of the matter ...

HOUSTON, Dec. 16, 2013 /PRNewswire/ — Freeport LNG Expansion, L.P. (Freeport LNG) and IFM Investors today announced that IFM Investors has entered into an agreement to invest approximately $1.3 ...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...

Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...

Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...

Australian investment manager IFM Investors will wind down its domestic private equity unit in coming years, citing a lack of scale to make it commercially viable and a focus on other global ...